Shots:
- Health Canada has approved the Jubbonti subcutaneous injection to treat osteoporosis and increase bone mass. The approval is based on the results of Phase I and Phase III clinical studies results that show Jubbonti has the same safety and risk as the reference medicine (Prolia)
- This human mAb and ligand inhibitor (bone metabolism regulator) is also approved to treat all five indications, just like the reference medicine
- Sandoz continued the expansion of Jubbonti and will be available in the Canadian market in the coming month as a 60 mg/mL solution in a single-use prefilled syringe
Ref: Sandoz | Image: Sandoz | Press Release
Related News:- Biocon Biologics Enters into a Collaboration Agreement with Sandoz for the Commercialization of Ogivri (biosimilar, trastuzumab) and Abevmy (biosimilar, bevacizumab) to Treat Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
